DOCSLIB.ORG

Nonsteroidal Anti-Inflammatory Agents Differ in Their Ability to Suppress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nonsteroidal Anti-Inflammatory Agents Differ in Their Ability to Suppress Oncogene (2004) 23, 9247–9258 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-jB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Yasunari Takada1, Anjana Bhardwaj1, Pravin Potdar1 and Bharat B Aggarwal*,1 1Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, TX 77030, USA Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Introduction aspirin have been shown to suppress transcription factor NF-jB, which controls the expression of genes such as Owing to its analgesic and anti-inflammatory effects, cyclooxygenase (COX)-2 and cyclin D1, leading to aspirin (acetylsalicylic acid), first synthesized in 1897, inhibition of proliferation of tumor cells. There is no was approved for the treatment of rheumatoid arthritis systematic study as to how these drugs differ in their ability in 1899 (Botting, 1999). Since then several other to suppress NF-jB activation and NF-jB-regulated gene nonsteroidal anti-inflammatory drugs (NSAIDs) have expression or cell proliferation. In the present study, we been synthesized and approved for human use. The anti- investigated the effect of almost a dozen different commonly inflammatory and analgesic effects of NSAIDs have used NSAIDs on tumor necrosis factor (TNF)-induced NF- been shown to be due to their ability to inhibit the jB activation and NF-jB-regulated gene products, and on enzymatic activity of cyclooxygenases (COXs), which cell proliferation. Dexamethasone, an anti-inflammatory convert arachidonic acid to prostaglandins (PGs) (Vane, steroid, was included for comparison with NSAIDs. As 1971). Aspirin is one of the most widely used drugs, with indicated by DNA binding, none of the drugs alone an average yearly consumption of 30 g/person in the activated NF-jB. All compounds inhibited TNF-induced industrialized countries (Roth and Calverley, 1994) and NF-jB activation, but with highly variable efficacy. The a daily consumption in the United States alone of 50% inhibitory concentration required was 5.67, 3.49, 3.03, 35 000 kg (Jack, 1997). 1.25, 0.94, 0.60, 0.38, 0.084, 0.043, 0.027, 0.024, and In most cases, aspirin or another NSAID either 0.010 mM for aspirin, ibuprofen, sulindac, phenylbutazone, prevents or delays the onset of the disease. Extensive naproxen, indomethacin, diclofenac, resveratrol, curcumin, research has shown that aspirin has a potential in the dexamethasone, celecoxib, and tamoxifen, respectively. All treatment of a wide variety of inflammatory diseases drugs inhibited IjBa kinase and suppressed IjBa degrada- including cancer, arthritis, cardiovascular diseases, and tion and NF-jB-regulated reporter gene expression. They Alzheimer’s disease (O’Neill, 1998). For instance, also suppressed NF-jB-regulated COX-2 and cyclin D1 aspirin has been found effective against colon cancer, protein expression in a dose-dependent manner. All especially familial adenomatous polyposis coli, a her- compounds inhibited the proliferation of tumor cells, with editary precancerous disease caused by the loss of the 50% inhibitory concentrations of 6.09, 1.12, 0.65, 0.49, tumor suppressor gene adenomatous polyposis coli 1.01, 0.19, 0.36, 0.012, 0.016, 0.047, 0.013, and 0.008 mM (Giercksky, 2001). Both preventive and therapeutic for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, affects of aspirin have been reported against colorectal indomethacin, diclofenac, resveratrol, curcumin, dexa- adenomas (Baron et al., 2003; Sandler et al., 2003). methasone, celecoxib, and tamoxifen, respectively. Overall Moysich et al. (2002) found that regular aspirin use may these results indicate that aspirin and ibuprofen are least be associated with reduced risk of lung cancer. When the potent, while resveratrol, curcumin, celecoxib, and tamox- analyses were restricted to former and current smokers, ifen are the most potent anti-inflammatory and antiproli- participants with the lowest cigarette exposure tended to ferative agents of those we studied. benefit most from the potential chemopreventive effect Oncogene (2004) 23, 9247–9258. doi:10.1038/sj.onc.1208169 of aspirin. Published online 18 October 2004 How aspirin and other NSAID mediate their effects is not fully understood. Whether inhibition of COX-1 Keywords: NSAID; NF-kB; IkBa; COX-2; cyclin D1; (constitutive) or COX-2 (inducible) activity is a major proliferation mechanism of its action has been questioned. For instance, Goel et al. (2003) showed that growth inhibition of human colon cancer cells by aspirin is *Correspondence: BB Aggarwal; E-mail: [email protected] through COX-independent mechanisms and is due to Received 21 April 2004; revised 1 September 2004; accepted 1 September the change in expression of DNA mismatch repair 2004; published online 18 October 2004 proteins (Goel et al., 2003). Similarly, Williams et al. Downregulation of NF-jB, COX-2, cyclin D1, and proliferation by NSAID Y Takada et al 9248 (2000) showed that the cytotoxic effects of celecoxib, were prepared and analysed for NF-kB activation by another NSAID, were independent of COX-2 inhibition electrophoretic mobility shift assay (EMSA). As shown because similar effects were observed in COX-2 ( þ / þ ), in Figure 2, none of the NSAIDs by themselves COX-2 ( þ /À) and COX-2 (À/À) fibroblasts. activated NF-kB. TNF-induced NF-kB activation, Generally, a strong correlation has been found however, was inhibited by all NSAID in a dose- between inflammation and cancer (Coussens and Werb, dependent manner. The 50% inhibitory concentration 2002), suggesting that cancer is an inflammatory disease. required was 5.67, 3.49, 3.03, 1.25, 0.94, 0.60, 0.38, Celecoxib, however, has been shown to reduce pulmon- 0.084, 0.043, 0.027, 0.024, and 0.01 mM for aspirin, ary inflammation but not lung tumorigenesis in mice ibuprofen, sulindac, phenylbutazone, naproxen, indo- (Kisley et al., 2002). Thus, novel targets to explain the methacin, diclofenac, resveratrol, curcumin, dexametha- effects of NSAID are being sought. Nuclear factor NF- sone, celecoxib, and tamoxifen, respectively (Table 1). kB is one such target that has been shown to mediate Based on IC50, aspirin was least potent and tamoxifen inflammation and suppress apoptosis, and it is com- was most potent (567-fold). The IC50 of celecoxib was monly overexpressed in cancer cells (Bharti and comparable with dexamethasone (236- vs 210-fold). Aggarwal, 2002). The expression of most genes that Since NF-kB is a family of proteins, various are involved in inflammation (e.g. COX-2) or in cellular combinations of Rel/NF-kB protein can constitute an proliferation (e.g. cyclin D1) are regulated by NF-kB. active NF-kB heterodimer that binds to a specific Thus, both antiproliferative and anti-inflammatory sequence in DNA (Ghosh and Karin, 2002). To show effects of NSAID can be explained through their ability that the retarded band visualized by EMSA in TNF- to suppress NF-kB. Although aspirin was the first treated cells was indeed NF-kB, we incubated nuclear NSAID shown to suppress NF-kB (Kopp and Ghosh, extracts from TNF-activated cells with antibodies to 1994), now several NSAID have been shown to suppress either the p50 (NF-kB1) or the p65 (RelA) subunit of NF-kB activation (Kazmi et al., 1995; Scheuren et al., NF-kB. Both shifted the band to a higher molecular 1998; Yamamoto et al., 1999; Chuang et al., 2002; mass (Figure 2b), thus suggesting that the TNF- Bryant et al., 2003). activated complex consisted of p50 and p65 subunits. How various NSAID differ in their ability to suppress Preimmune serum (PIS) had no effect on NF-kB NF-kB activation, NF-kB-regulated gene expression, complex. Excess unlabeled NF-kB oligonucleotide and proliferation has not been examined and is the focus (100-fold) caused complete disappearance of the band of the current study. We examined 11 different NSAID and no effect by using mutant NF-kB oligonucleotide. for inhibition of tumor necrosis factor (TNF)-induced To further determine the specificity of the effect of NF-kB activation, IkBa degradation, NF-kB reporter NSAIDs on NF-kB, we examined its effect on the gene expression, expression of cyclin D1 and COX-2, transcription factor Oct-1. For this, cells were treated and antiproliferative effects. with the indicated concentrations of aspirin or curcumin for 4 h, the nuclear extracts were prepared, and the extracts examined for binding to labeled oligonucleo- Results tides containing specific binding sites for Oct-1 by In the present study, we investigated the relative anti- inflammatory and antiproliferative effects of most commonly used NSAIDs by examining their effects on Table 1 NSAIDs inhibit TNF-induced NF-kB activation and on cell TNF-induced NF-kB activation, IkBa kinase, IkBa proliferation degradation, NF-kB-regulated reporter gene expression, NSAID 50% inhibitory concentration (IC50) NF-kB regulating proteins, and proliferation of tumor NF-kBa Cell viabilityb COX-1c COX-2c cells. We examined the effect of the oldest (aspirin) and the most recently identified (celecoxib) NSAIDs. In all, Aspirin 5.67 (1.0)d 6.09 (1.0) 1.7 >100 11 different NSAIDs, along with dexamethasone, were Ibuprofen 3.49 (1.6) 1.12 (5.4) 7.2 7.6 investigated. The similarities and dissimilarities in the Sulindac 3.03 (1.9) 0.65 (9.4) 1.9 55.0 Phenylbutazone 1.25 (4.5) 0.49 (12.4) N/A N/A chemical structure of these NSAIDs are shown in Naproxen 0.94 (6.0) 1.01 (6.0) 9.3 28.0 Figure 1. Indomethacin 0.60 (9.5) 0.19 (32.1) 0.013 1.0 Diclofenac 0.38 (14.9) 0.36 (16.9) 0.075 0.038 Resveratrol 0.084 (67.5) 0.012 (507.0) 30.0 39.0 NSAIDs inhibit TNF-induced NF-kB activation Curcumin 0.043 (131.0) 0.016 (380.0) N/A N/A Activation of NF-kB is one of the earliest events that Dexamethasone 0.027 (210.0) 0.047 (130.0) N/A N/A Celecoxib 0.024 (236.0) 0.013 (468.0) 1.2 0.83 mediate inflammation induced by various stimuli in Tamoxifen 0.010 (567.0) 0.008 (761.0) 15.0 95.0 most cells (Bharti and Aggarwal, 2002).
Load more

Recommended publications
  • Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
    Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ANALYSIS IN MILK BY QUECHERS AND LC-MS: LOW AND HIGH RESOLUTION DETECTION AND CONFIRMATION APPROACHES A. Rúbies1, L. Guo2, I. Beguiristain1, F. Centrich1, M. Granados2 1. Laboratori Agència de Salut Pública de Barcelona, 2. Departament de Química Analítica - Universitat de Barcelona. * INTRODUCTION NON-STEROIDAL ANTI-INFLAMATORY DRUGS (NSAIDs) Non-steroidal anti-inflammatory drugs (NSAIDs) are used as anti-inflammatory, analgesic and OXICAMS ANTHRANILIC ACID DERIVATIVES ACETIC ACID antipyretic drugs in medicine and veterinary. Their action mechanism is based on the blocking of PROPIONIC ACID DERIVATIVES DERIVATIVES the biosynthesis of prostaglandins. NSAIDs are highly effective and extensively used, but they have some adverse side effects, such as hepatotoxicity, renal disorders or allergic reactions. In the European Union, to assure food safety and protect consumers, maximum residue limits have been established for some authorised NSAIDs in food products. Therefore, high throughput and reliable analytical methodology is required for the effective control of NSAIDs in food from animal Flufenamic acid origin. Liquid chromatography (LC) coupled to mass spectrometry (MS) is currently the technique of choice in confirmatory analysis of NSAIDs residues. We present a new method for the determination of representative NSAIDs in milk based on QuEChERS methodology, LC-MS/MS and UHPLC-HRMS. Meloxicam Ketoprofen Diclofenac EU Maximum Residue Limits (MRLs) Recommended NSAIDs concentrations for NSAIDs in milk.
    [Show full text]
  • Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information
    ® Voltaren (diclofenac sodium enteric-coated tablets) Tablets of 75 mg Rx only Prescribing Information Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS.) • Voltaren® (diclofenac sodium enteric-coated tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Voltaren® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. Voltaren is available as delayed-release (enteric-coated) tablets of 75 mg (light pink) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in Voltaren include: hydroxypropyl methylcellulose, iron oxide, lactose, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium hydroxide, sodium starch glycolate, talc, titanium dioxide. CLINICAL PHARMACOLOGY Pharmacodynamics Voltaren® (diclofenac sodium enteric-coated tablets) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Voltaren, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Combination of Atorvastatin with Sulindac Or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the P65/B-Catenin/Cyclin D1 Signaling Pathway in Rats
    Published OnlineFirst July 15, 2011; DOI: 10.1158/1940-6207.CAPR-11-0222 Cancer Prevention Research Article Research Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/b-Catenin/Cyclin D1 Signaling Pathway in Rats Nanjoo Suh1,4, Bandaru S. Reddy1, Andrew DeCastro1, Shiby Paul1, Hong Jin Lee1, Amanda K. Smolarek1, Jae Young So1, Barbara Simi1, Chung Xiou Wang1, Naveena B. Janakiram2, Vernon Steele3, and Chinthalapally V. Rao2 Abstract Evidence supports the protective role of nonsteroidal anti-inflammatory drugs (NSAID) and statins against colon cancer. Experiments were designed to evaluate the efficacies atorvastatin and NSAIDs administered individually and in combination against colon tumor formation. F344 rats were fed AIN- 76A diet, and colon tumors were induced with azoxymethane. One week after the second azoxymethane treatment, groups of rats were fed diets containing atorvastatin (200 ppm), sulindac (100 ppm), naproxen (150 ppm), or their combinations with low-dose atorvastatin (100 ppm) for 45 weeks. Administration of atorvastatin at 200 ppm significantly suppressed both adenocarcinoma incidence (52% reduction, P ¼ 0.005) and multiplicity (58% reduction, P ¼ 0.008). Most importantly, colon tumor multiplicities were profoundly decreased (80%–85% reduction, P < 0.0001) when given low-dose atorvastatin with either sulindac or naproxen. Also, a significant inhibition of colon tumor incidence was observed when given a low-dose atorvastatin with either sulindac (P ¼ 0.001) or naproxen (P ¼ 0.0005). Proliferation markers, proliferating cell nuclear antigen, cyclin D1, and b-catenin in tumors of rats exposed to sulindac, naproxen, atorvastatin, and/or combinations showed a significant suppression.
    [Show full text]
  • Topical NSAID for Osteoarthritis Safe and Effective (Print)
    The Horse: Study: Topical NSAID for Osteoarthritis Safe and Effective (print) Study: Topical NSAID for Osteoarthritis Safe and Effective by: Stacey Oke, DVM, MSc February 26 2009 Article # 13686 Move over, Bute. In a new independent study, researchers at Colorado State University's Gail Holmes Equine Orthopaedic Research Center concluded that diclofenac liposomal cream (1% diclofenac sodium, trade name Surpass) is safer and more effective than phenylbutazone for treating discomfort associated with osteoarthritis in horses. Phenylbutazone, commonly known as "Bute," is a non-steroidal anti-inflammatory (NSAID) drug administered systemically (i.e., intravenously or orally) to help control the pain and inflammation caused by osteoarthritis in horses. "Considering that phenylbutazone and other NSAIDs are known to have important adverse effects in horses when used long-term and that these drugs are not able to alter the course of OA but only help control clinical signs, alternatives are needed," explained researcher David Frisbie, DVM, PhD, Dipl. ACVS. One such alternative is diclofenac liposomal cream--an NSAID that is applied to the skin overlying the affected joint(s) to control pain and inflammation of the tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal joints. This product is approved by the Food and Drug Administration and is the first product of its kind manufactured for horses. Results of this study were presented at the 2007 annual American Association of Equine Practitioners' conference and were recently published in the study, "Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis," in the February edition of the American Journal of Veterinary Research.
    [Show full text]
  • Indomethacin in Pregnancy: Applications and Safety
    Original Article 175 Indomethacin in Pregnancy: Applications and Safety Gael Abou-Ghannam, M.D. 1 Ihab M. Usta, M.D. 1 Anwar H. Nassar, M.D. 1 1 Department of Obstetrics and Gynecology, American University of Address for correspondence and reprint requests Anwar H. Nassar, Beirut Medical Center, Hamra, Beirut, Lebanon M.D., American University of Beirut Medical Center, P.O. Box 113-6044/B36, Hamra 110 32090, Beirut, Lebanon (e-mail: [email protected]). Am J Perinatol 2012;29:175–186. Abstract Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, Keywords renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the ► indomethacin patent ductus arteriosus have been reported with the use of indomethacin. Indometh- ► tocolysis acin has been also used in women with short cervices as well as in those with idiopathic ► preterm labor polyhydramnios. This article describes the mechanism of action of indomethacin and its ► short cervix clinical applications as a tocolytic agent in women with PTL and cerclage and its use in ► polyhydramnios the context of polyhydramnios. The fetal and neonatal side effects of this drug are also ► fetal side effects summarized and guidelines for its use are proposed. Preterm labor (PTL) is a major cause of neonatal morbidity in women with PTL and cerclage and its use in the context of and mortality worldwide.1 Care of premature infants has polyhydramnios.
    [Show full text]
  • Ketorolac Tromethamine Injection
    ! • unusual weight gain Ketorolac Tromethamine Injection, USP Rx only Table 1: Table of Approximate Average Pharmacokinetic Parameters (Mean ± SD) IV-Administration: In normal subjects (n=37), the total clearance of 30 mg IV-administered ketorolac tromethamine was Anaphylactoid Reactions 0.030 (0.017-0.051) L/h/kg. The terminal half-life was 5.6 (4.0-7.9) hours. (See Kinetics in Special Populations for use of • skin rash or blisters with fever FOR IV/IM USE (15 mg/mL and 30 mg/mL) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ketorolac tromethamine. Oral† Intramuscular* Intravenous Bolus‡ IV dosing of ketorolac tromethamine in pediatric patients.) Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in • swelling of the arms and legs, hands and feet FOR IM USE ONLY (60 mg/2 mL (30 mg/mL) asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm Pharmacokinetic CLINICAL STUDIES These are not all the side effects with NSAID medicines. Talk to your healthcare provider or Parameters 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS – Pre-existing Asthma). Emergency WARNING (units) Adult Patients help should be sought in cases where an anaphylactoid reaction occurs. pharmacist for more information about NSAID medicines. Bioavailability 100% In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV Cardiovascular Effects Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days (extent) in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
    [Show full text]
  • List Item Frequently Asked Questions on Phenylbutazone in Horsemeat
    15 April 2013 Frequently asked questions on Phenylbutazone in horsemeat 1. What is phenylbutazone? 2. What is the situation regarding phenylbutazone in food in the EU? 3. Why was phenylbutazone banned for use in food-producing animals? 4. What are the known toxic effects of phenylbutazone? 5. What is the likelihood of consumers being exposed to phenylbutazone in horsemeat? 6. What were EFSA and EMA asked to do by the European Commission? 7. What information did EFSA and EMA consider in their risk assessment of phenylbutazone? 8. What are the main conclusions of the joint statement? 9. What did the report conclude with regard to the potential risk for consumers? 10. What recommendations did EFSA and EMA make to further reduce the risk of phenylbutazone entering the food chain? 11. What is EFSA’s role with regards to the management of issues such as the contamination of beef products with horsemeat? 12. What is EMA’s contribution to this joint risk assessment regarding the public health implications of phenylbutazone in horsemeat? 1. What is phenylbutazone? Phenylbutazone – sometimes also referred to as “bute” – is a substance that falls into the class of drugs known as non steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are routinely used as painkillers in human and veterinary medicine. Phenylbutazone was introduced in 1949 as a human medicine for the treatment of rheumatoid arthritis and gout. These days it is used only under specialist supervision in patients who suffer from a severe form of arthritis where other treatments have not worked. Phenylbutazone is used for the treatment of pain and fever in horses and dogs.
    [Show full text]
  • Original Paper Enhancement of Chemotherapeutic Drug Toxicity To
    European Journal of Cancer, Vol. 34, No. 8, pp. 1250±1259, 1998 # 1998 Elsevier Science Ltd. All rights reserved Pergamon Printed in Great Britain 0959-8049/98 $19.00+0.00 PII: S0959-8049(98)00045-8 Original Paper Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-steroidal Anti-in¯ammatory Drugs (NSAIDs) C.P. DuVy, C.J. Elliott, R.A. O'Connor, M.M. Heenan, S. Coyle, I.M. Cleary, K. Kavanagh, S. Verhaegen, C.M. O'Loughlin, R. NicAmhlaoibh and M. Clynes National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, Dublin 9, Ireland The eVect on cytotoxicity of combining a range of clinically important non-steroidal anti-in¯amma- tory drugs (NSAIDs) with a variety of chemotherapeutic drugs was examined in the human lung cancer cell lines DLKP, A549, COR L23P and COR L23R and in a human leukaemia line HL60/ADR. A speci®c group of NSAIDs (indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) all at non-toxic levels, signi®cantly increased the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine, but not the other vinca alkaloids vinblastine and vinorelbine. Asubstantial number of other anticancer drugs, including methotrexate, 5-¯uorouracil, cytarabine, hydroxyurea, chlorambucil, cyclophosphamide, cisplatin, carboplatin, mitoxantrone, actinomycin D, bleomycin, paclitaxel and camptothecin, were also tested, but displayed no synergy in combination with the NSAIDs. The synergistic eVect was concentration dependent. The eVect appears to be independent of the cyclo-oxygenase inhibitory ability of the NSAIDs, as (i) the synergistic combination could not be reversed by the addition of prostaglandins D2 or E2; (ii) sulindac sulphone, a metabolite of sulindac that does not inhibit the cyclooxygenase enzyme, was positive in the combination assay: and (iii) many NSAIDs known to be cyclo-oxygenase inhibitors, e.g.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]